BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.70
+0.05 (0.16%)
Apr 2, 2025, 1:30 PM CST
-16.25%
Market Cap 3.92B
Revenue (ttm) 167.65M
Net Income (ttm) -116.47M
Shares Out 124.26M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 55,355
Average Volume 119,716
Open 32.30
Previous Close 31.65
Day's Range 31.40 - 32.30
52-Week Range 31.10 - 41.25
Beta 0.61
RSI 40.25
Earnings Date Mar 3, 2025

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2024, BioGend Therapeutics's revenue was 167.65 million, an increase of 52.53% compared to the previous year's 109.91 million. Losses were -116.47 million, -25.49% less than in 2023.

Financial Statements

News

There is no news available yet.